UK In Silico Regulatory Innovation Task Force
Mission: Nurture a cross-sector UK in silico trials community for regulatory science & innovation to produce evidence and harmonize standards in the UK accelerating in silico adoption in regulations
The UK In Silico Regulatory Innovation Task Force is making waves in the field of medical research. Led by Alejandro Frangi (University of Manchester) and David Flynn (Boston Scientific), this group is dedicated to nurturing a collaborative environment that advances in silico clinical trials and paves the way for their wider adoption.
Their efforts hold the potential to revolutionise medical research, leading to faster development of life-saving treatments for patients worldwide.
The Task Force champions UK standardisation efforts through organisations like BSI (British Standards Institution) and fosters collaboration with international counterparts like the FDA (US Food and Drug Administration) and EMA (European Medicines Agency). This collaborative effort will ensure consistency and facilitate the global acceptance of in silico trials.
Goals
- Facilitating intra-UK and UK-international dialogue promoting adoption of in silico regulatory science and innovation.
- Develop the evidence for in silico trials and predictive medicine as a response to the TIGR Report.
- Actively engage with UK Government, Trade Associations, Standardisation Bodies, Regulators & Policy makers.
- Map out the economic impact and supply chain for the UK economy of in silico regulatory science and innovation.
- Promote UK standardisation efforts (e.g., via BSI etc.) with international standardisation initiatives.
- Promote collaboration between MHRA, FDA and EMA around medical products regulatory science and innovation
